Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: Can we afford to do it? (Can we afford not to?).
Exner
D V
DV
Cardiovascular Research Group, University of Calgary, Calgary, Canada. exner@ucalgary.ca
Klein
G J
GJ
Prystowsky
E N
EN
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy; D000529:Complementary Therapies; D001026:Coronary Artery Bypass; D003362:Cost-Benefit Analysis; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000191:economics* / Q000706:statistics & numerical data; D005858:Germany / Q000453:epidemiology; D006323:Heart Arrest / Q000628:therapy; D006331:Heart Diseases / Q000150:complications / Q000191:economics / Q000628:therapy*; D006801:Humans; D008133:Long QT Syndrome / Q000628:therapy; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013610:Tachycardia / Q000628:therapy
D000889:Anti-Arrhythmia Agents